Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies

Next Previous
Trial Profile

Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MST 0312 (Primary)
  • Indications Solid tumours
  • Focus First in man; Therapeutic Use
  • Acronyms MST-0312-1001; STARLYS
  • Sponsors Mestag Therapeutics

Most Recent Events

  • 14 Apr 2026 According to a Mestag Therapeutics media release, MST-0312 is anticipated to enter clinic mid-2026 with the initiation of the Phase 1 STARLYS trial.
  • 26 Mar 2026 New trial record
  • 18 Mar 2026 According to a Mestag Therapeutics media release, the closing of a $40 million financing supported by leading life science investors SV Health Investors, Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation JJDC, Inc., Forbion, GV (Google Ventures) and Northpond Ventures and the financing will support the Phase 1 STARLYS clinical study, which is anticipated to start in cancer patients in mid-2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top